Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
20 Noviembre 2024 - 10:15AM
Edgar (US Regulatory)
FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
20 November 2024 16:00 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca
PLC (the Company) announces that it was notified on 20 November
2024 that Tony Mok, Non-Executive Director, purchased 3,000 of the
Company's American Depositary
Shares (ADSs) on 19 November 2024, as set out
below. Two ADSs are equivalent to
one of the Company's ordinary shares of $0.25
each.
|
PDMR
|
Position
|
Nature of the
transaction
|
Quantity
|
Price
|
|
Tony Mok
|
Non-Executive Director
|
Purchase of ADSs
|
3,000
|
US$63.40
|
Further
details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(since it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Tony
Mok
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive
Director
|
|
b)
|
Initial
notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification
code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
|
b)
|
Nature
of the transaction
|
Purchase of AstraZeneca PLC American Depositary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
USD
63.398167
|
3,000
|
|
d)
|
Aggregated
information
-
Aggregated volume
-
Price
|
Not
applicable - single transaction
|
|
e)
|
Date
of the transaction
|
19
November 2024
|
|
f)
|
Place
of the transaction
|
XNAS
|
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca's innovative medicines are sold in more
than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For
details on how to contact the Investor Relations Team, please
click here. For Media
contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
20 November 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
AstraZeneca (NASDAQ:AZN)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
